A Randomized, Parallel-group, Placebo-controlled, Double-blind Phase 1 Study in Healthy HIV-uninfected Adults to Evaluate Safety/Tolerability and Immunogenicity of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C gp140
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Ad26 Mos HIV (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Janssen Infectious Diseases BVBA; Janssen Vaccines and Prevention
- 18 Sep 2017 Planned End Date changed from 15 Jan 2018 to 3 Jan 2019.
- 18 Sep 2017 Planned primary completion date changed from 1 Dec 2017 to 19 Feb 2018.
- 20 Jun 2017 Planned End Date changed from 1 Jan 2018 to 15 Jan 2018.